Tag Archives: SUNNYVALE

Business, Finance, Occupation & Industry

Amarantus BioScience to Hold Business Update Conference Call on April 16

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Amarantus BioScience to Hold Business Update Conference Call on April 16

SUNNYVALE, Calif.–(BUSINESS WIRE)– Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it will hold a conference call on Tuesday, April 16, 2013 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to provide an update on its business and conduct a question and answer session with investors.

Individuals interested in listening to the conference call may do so by dialing 877-407-8033, or for international callers 201-689-8033. The call is also being webcast, and can be accessed from the Company’s Web site (www.amarantus.com) and at www.InvestorCalendar.com.

A telephone replay will be available through May 1, 2013 by dialing 877-660-6853, or for international callers 201-612-7415, and entering the Conference ID #: 411612. The webcast replay will be available for 90 days following the completion of the call.

During the call Amarantus Chief Executive Officer Gerald Commissiong will recap key accomplishments of 2012 and the first quarter of 2013, provide clarity on the Company’s recently updated business model and discuss business and product development initiatives planned for the remainder of 2013.

About Amarantus BioScience

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company is focused on developing unique products and proprietary technologies for the potential treatment and/or diagnosis of Parkinson’s disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF“) and is developing MANF-based products as treatments for neurological disorders where there is a significant unmet medical need. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and related nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in testing for Parkinson’s disease, as well as statements about expectations, plans and prospects of the development of Amarantus’ diagnostic product candidates. These forward-looking statements are subject to a number of risks, …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Amarantus BioScience Modifies Business Structure to Support Product Development Strategy

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Amarantus BioScience Modifies Business Structure to Support Product Development Strategy

Corporation will change name to Amarantus Bioscience Holdings, Inc.

SUNNYVALE, Calif.–(BUSINESS WIRE)– Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it will adopt a holding company structure with separate business units in order to more effectively develop its various assets. Reflecting the change in structure, the corporation will change its name to Amarantus Bioscience Holdings, Inc.

Initially, the Company will form two business units: Amarantus Therapeutics, centered on its patented therapeutic protein Mesencephalic Astrocyte Neurotrophic Factor (MANF), and Amarantus Diagnostics, focused on developing the LymPro Blood Test for Alzheimer’s disease and the NuroPro Blood Test for Parkinson’s disease. Currently, MANF is in preclinical testing as a potentially disease-modifying treatment for Parkinson’s disease, and the two diagnostic tests are being prepared for Phase 2 studies. The Company will also evaluate the acquisition/in-licensure of clinical-stage drug candidate to complement MANF within the Amarantus Therapeutics subsidiary, and may evaluate additional strategic significantly undervalued opportunities over time using its deep industry knowledge and connections.

“While our near-term development objectives remain the same, the new structure will allow us to allocate capital more efficiently, and form management teams specific to each business or product line,” said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience. “We will also be able to create new business units to leverage other assets we already own, such as our PhenoGuard Protein Discovery platform, or that we may acquire. Additionally, we have decided not to spinoff Amarantus Diagnostics at this time, and will re-evaluate the potential spinoff of various business units as the situation with each entity unfolds.”

In conjunction with the new business structure and name change, the Company’s common stock will be given a new CUSIP code for the clearing and settlement of trades following confirmation with the various authorities. The Company will disclose the exact timing of this change in a future regulatory filing once final timing information is available.

About Amarantus BioScience

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s disease, Traumatic …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Pixelworks® and ACCESS Collaborate on Officeviewer to Enable Content Viewing and Presentations witho

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Pixelworks ® and ACCESS Collaborate on Officeviewer to Enable Content Viewing and Presentations without a PC

Officeviewer enables projection capability without a PC using USB host

SAN JOSE, Calif. & SUNNYVALE, Calif.–(BUSINESS WIRE)– Pixelworks, Inc. (NAS: PXLW) , a pioneer in innovative video and display processing technology, and ACCESS CO., LTD, a global provider of advanced software technologies to the mobile and beyond-PC markets, today announced the companies are collaborating on Officeviewer to bring projection capability without a PC to a full range of projectors — from traditional mainstream projectors to small LED or laser-based portable and pocket projectors. Officeviewer offers users the convenience of using a portable USB thumb drive to view content and make presentations when a PC isn’t available or convenient.

As part of this collaboration, ACCESS ported its NetFront™ Document Viewer to Pixelworks’ existing platform of digital projector solutions. Officeviewer leverages USB host functionality in Pixelworks’ connected display processors, such as the Topaz platform family, to effectively eliminate the need for a PC to make presentations. The Officeviewer software solution is now available for integration by customers of new and existing Pixelworks SoC projector platforms, including the Company’s latest generation Topaz family of display processors.

“ACCESS and Pixelworks, respective leaders in software and projectors, have successfully collaborated to bring this innovative solution to market and improve the user experience for our customers,” said Graham Loveridge, Sr. Vice President of Marketing at Pixelworks. “This projection capability will be available for a range of platforms, including the Topaz SoC family, and will ultimately be designed into nearly every leading projector brand. As such, we expect giving a presentation or viewing content without a PC to eventually become mainstream.”

“Similar to the growing trend of projection capability without a PC, viewing or sharing documents and content across connected devices has become a standard expectation for consumers in a connected world,” said Kiyoyasu Oishi, Senior Executive Officer, Global Business Unit, ACCESS CO., LTD. “By combining these projection and document viewing technologies, consumers will no longer need to use a PC to present and share documents, making it simpler and more efficient to work and collaborate.”

Features of Officeviewer include:

Business, Finance, Occupation & Industry

Mellanox FDR 56Gb/s InfiniBand Powers Stampede Supercomputer, Now Fully Deployed at Texas Advanced C

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Mellanox FDR 56Gb/s InfiniBand Powers Stampede Supercomputer, Now Fully Deployed at Texas Advanced Computing Center

One of the most powerful supercomputing systems in the world, Stampede utilizes Mellanox FDR 56Gb/s InfiniBand to provide leading scalable performance

SUNNYVALE, Calif. & YOKNEAM, Israel–(BUSINESS WIRE)– Mellanox® Technologies, Ltd. (NAS: MLNX) (TASE: MLNX), a leading supplier of high-performance, end-to-end interconnect solutions for data center servers and storage systems, today announced that its end-to-end FDR 56Gb/s InfiniBand is now deployed and live in the Stampede supercomputer at the Texas Advanced Computing Center (TACC) at The University of Texas at Austin. Stampede is the most powerful supercomputing system in the National Science Foundation Extreme Science and Engineering Discovery Environment (XSEDE), and one of the most powerful supercomputing systems in the world. TACC introduced Stampede to the public on March 27.

Stampede integrates thousands of individual Dell servers with Mellanox FDR 56Gb/s InfiniBand SwitchX based switches and ConnectX-3 adapter cards with PCI Express 3.0 to drive performance of nearly 10 petaflops.

“The InfiniBand network was easy to deploy and delivers incredible application performance on a consistent basis,” said Tommy Minyard, director of Advanced Computing Systems, TACC. “Utilizing Mellanox FDR 56Gb/s InfiniBand provides us with extremely scalable, high performance — a critical element as Stampede is designed to support hundreds of computationally- and data-intensive science applications from around the United States and the world.”

“Stampede is one of the highest profile supercomputers being deployed in 2013,” said Gilad Shainer, vice president of marketing at Mellanox Technologies. “Mellanox FDR 56Gb/s InfiniBand is differentiated by the low latency and accelerated speed which enables the fastest data delivery. With a system the size of Stampede, where scalability is of the greatest of importance, the role of InfiniBand is significant.”

Stampede supports national scientific research into weather forecasting, climate modeling, drug discovery and energy exploration and production.

Supporting Resources:

About Mellanox

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Amarantus BioScience Reports Positive MANF Data in Neuroprotection Animal Models of Parkinson's Dise

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Amarantus BioScience Reports Positive MANF Data in Neuroprotection Animal Models of Parkinson’s Disease

Company’s proprietary therapeutic appears to protect key dopamine-producing brain function

SUNNYVALE, Calif.–(BUSINESS WIRE)– Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today reported positive preclinical data for its lead therapeutic MANF in neuroprotection 6-hydroxydopamine (6-OHDA) rat models of Parkinson’s disease. The data show that MANF protects the integrity of dopamine producing neurites in the striatum.

“Our scientists are excited by this data, which not only demonstrates the efficacy of MANF, but its superiority to GDNF, as well,” said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience. “Based on this study, we believe MANF plays a role in maintaining brain connectivity, specifically the dopaminergic system of the basal ganglia network, which reinforces the potential of MANF as a disease-modifying treatment for Parkinson’s.”

In the neuroprotection study, MANF was delivered into the substantia nigra shortly before injection of the toxin 6-OHDA into the striatum. Four weeks later the animals were sacrificed and the density of dopaminergic neuron projections in the striatum was determined. The protection of neuron health, as measured by the density of neurite terminals, was evident in all three areas of the striatum examined. The effects of a single MANF treatment were evident after four weeks, indicating the effects of MANF protection are sustained. Furthermore, the highest level of neurite density was found at the highest dosage of MANF. Importantly, the neurite density measured under treatment with MANF was statistically significantly better than shown for both vehicle control and a standard dosage of Glial cell-Derived Neurotrophic Factor (GDNF). GDNF is currently in clinical trials for Parkinson’s disease and considered the current benchmark in the field. The data summarized here suggests that MANF may have advantages over GDNF for the clinical treatment of Parkinson’s disease.

“The data on MANF continues to return more favorable results than other molecules currently in clinical development as disease-modifying treatments for Parkinson’s disease,” said Dr. Joseph Rubinfeld, Amgen co-founder and current member of the Company’s Board of Advisors. “We intend to conduct select additional experiments to understand why this appears to be the case while we continue the IND-enabling studies that have already been initiated. We believe these additional data points will further distinguish MANF from competitors in the field, and will deliver significant value in the near-term.”

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

CSC Transforms Supply Chain through Ariba

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

CSC Transforms Supply Chain through Ariba

Leading provider of technology-enabled business solutions leverages cloud-based applications and business network to improve performance and profits

SUNNYVALE, Calif.–(BUSINESS WIRE)– Ariba, an SAP Company and the world’s business commerce network, today announced that as part of a sweeping initiative aimed at streamlining key business processes, CSC will tap into the Ariba® Network and leverage a number of the cloud-based applications delivered on it to streamline and enhance its procurement process.

“Over the past five decades, technology has radically changed the world we live in,” said Mike Shove, Vice President, Global Supply Chain and Demand Management, CSC. “We have remained at the forefront of our business because we have understood how to use technology change and innovation to deliver value to our clients. By applying this same discipline to our own supply chain – and doing it in the cloud – we can quickly drive improvements across our business that enhance our performance and, ultimately, the results that we help our clients to achieve.”

Among the Ariba applications that CSC will use to achieve its objectives: Ariba Sourcing On-Demand™, Ariba Procure-to-Pay™,Ariba Contract Management™and Ariba Supplier Information and Performance Management™

With Ariba Sourcing, CSC can create a standard, best-in-class procurement process. Using Ariba Procure-To-Pay it can control and monitor this process and drive immediate process efficiencies and cost savings. With Ariba Contract Management, the company can connect directly with customers when creating, negotiating, executing, and managing the ongoing administration of contracts and drive greater efficiency, lower administrative costs, and improved relationships that result in higher-value agreements. And through Ariba Supplier Information and Performance Management, CSC can more efficiently discover, connect and collaborate with key trading partners, monitor and drive their performance and assess compliance and manage risk on an ongoing basis.

CSC will integrate these solutions with its SAP system, to increase its efficiencies and savings and maximize its investments. Integration is fast and easy for SAP customers like CSC thanks to the open nature of the Ariba Network and rapid deployment solutions that allow for:

Business, Finance, Occupation & Industry

InvenSense® MPU-9150 Selected for Kopin's Golden-i® 3.8 Headset Computer

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

InvenSense ® MPU-9150 Selected for Kopin’s Golden-i ® 3.8 Headset Computer

MPU-9150 nine-axis solution enables intuitive motion control for wearable computing technology

SUNNYVALE, Calif.–(BUSINESS WIRE)– InvenSense, Inc. (NYS: INVN) , the leading provider of MotionTracking™ devices, announced that its MPU-9150 is enabling Kopin’s Golden-i 3.8 Headset Computer, a hands-free mobile computing and wireless headset utilizing natural speech recognition and InvenSense MotionTracking technology. Golden-i provides ‘First Responders‘ such as fire fighters, police and paramedics with critical real-time information required to perform their jobs safely and efficiently. Situational information is presented on Kopin’s QHD micro-display while the user intuitively navigates the information on a head-mounted device via voice and head gesture control. MPU-9150 is the world’s first nine-axis MotionTracking device with integrated 3-axis gyroscope, 3-axis accelerometer and 3-axis compass optimized for the low-power and high-performance requirements of the industrial wearable computing market.

“We are pleased that Kopin, a market leader in hands-free wearable computing technology, has selected our MPU-9150 for integration into the new Golden-i headset to drive innovation and enhance user experience,” said Ali Foughi, Vice President of Marketing and Business Development at InvenSense. “InvenSense is the recognized performance leader of motion sensing technology serving consumer electronics applications. Our 9-axis technology now empowers new products in a broad range of markets such as light industrial, wearable headsets, health and fitness, mobile phones, tablets, e-readers, and other emerging applications.”

“InvenSense was decisively selected as the motion tracking solution to provide Golden-i 3.8 the responsiveness and low-power consumption required for a “Hands-Free” computing headset,” said Jeffrey Jacobsen, Kopin’s Sr. Advisor to CEO and Golden-i Program Manager. “There is a lot more to the MPU-9150 than a few gyros and accelerometers. The 9-axis tracking enables Golden-i 3.8 to achieve world-class precision indoor location navigation, inertial stabilization for real-time streaming video and telephoto viewing when highly mobile. We believe the InvenSense MPU-9150 device is in a class all by itself.”

For information about Golden-i 3.8 “Hands-Free Computing and Communications Headsets, please visit www.mygoldeni.com. For additional information about the InvenSense MPU-9150 MotionTracking device, please visit our website at www.invensense.com or contact InvenSense Sales at sales@invensense.com.


About InvenSense

InvenSense Inc. (NYS: INVN) is the …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Business Blooms at Fleurop through Ariba

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Business Blooms at Fleurop through Ariba

German floral retailer creates simplified, consumer-like shopping experience for corporate customers, boosting sales and use of flowers

SUNNYVALE, Calif.–(BUSINESS WIRE)– Flowers are big business. And for Fleurop, the leading floral partner network with more than 7,000 stores in Germany, business is blooming. With the help of Ariba, an SAP company and the world’s business commerce network, Fleurop has established an efficient portal for its corporate customers, who now use flowers far more often as an emotional and personal touch in their communications.

“Online shopping isn’t just for consumers anymore. Businesses want to be able to buy things in the same fast and easy manner,” according to Achim Oberhauser, Team Leader, Corporate Service, Fleurop. “Through Ariba, we have created a new consumer-like shopping experience for our corporate customers with a fully automated process that is consistent with their purchasing policies, while at the same time offering the full flexibility and bespoke service of real stores. It truly is the best of both worlds.”

To enable this consumer experience, Fleurop joined the Ariba® Network™, the world’s leading and largest open trading platform, and implemented Ariba PunchOut™ catalogs.

“We offer our customers tailored product catalogs with bouquets, plants, floral arrangements, and gift ideas, which can be filtered by price, category, occasion, and other aspects,” Oberhauser adds. “We can also offer highly life-like floral bouquets arranged according to a company’s corporate design. And the option to order free-text arrangements offers maximum flexibility for individual needs. And the best thing about our catalog is that customers can choose from 7,000 stores, and order their product from the store they know and trust. This significantly increases user acceptance.”

As a result of the automated process, Fleurop has greater transparency into orders and the invoices associated with them. Purchase order data is transferred to the system at the Fleurop head offices without any integration gaps, and sent to the relevant partner store for processing. Invoicing is executed centrally and automatically as a one-off electronic bill. Orders and invoices have fewer errors and the cost and time required to fill and process them has been dramatically reduced.

Fleurop’s customers benefit from this streamlined process, seeing efficiencies and, on average, savings of €35 in administrative costs per arrangement ordered.

“To succeed in today’s volatile and competitive economy, companies must find faster and smarter ways to connect and do …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Amarantus BioScience, Brewer Sports International and TCMG Announce #C4CT Concussion Awareness Confe

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Amarantus BioScience, Brewer Sports International and TCMG Announce #C4CT Concussion Awareness Conference

Conference will feature sports and neurology experts discussing concussion issues with an emphasis on addressing and identifying research, development and treatment opportunities

SUNNYVALE, Calif.–(BUSINESS WIRE)– Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, Brewer Sports International (BSI) and Toi Cook Management Group (TCMG) today announced joint hosting of the Coalition for Concussion Treatment (#C4CT) Concussion Awareness Conference (#C4CT Conference) in Minneapolis on June 19, 2013 at the Minneapolis Club.

The #C4CT Conference is the opening event of the three-day Brewer Sports Symposium, which also includes the 3rd Annual Sports Law for Rookies and Veterans CLE and Sports and Social Impact seminar. The #C4CT Conference will focus on important scientific, medical, translational and prevention-related topics of Traumatic Brain Injuries (TBI) and their long-term impacts on athletes and soldiers. Conference panels will include industry experts, international business leaders and current and former professional athletes. The Brewer Sports Symposium is part of the 8th Annual Blue Carpet Celebrity Weekend hosted by The Jack Brewer Foundation.

“Traumatic Brain Injuries and their effects on amateur and professional football players are emerging as a rallying point to better understand the brain and how we can improve currently available methods to treat it,” said Gerald E. Commissiong, President and CEO of AMBS. “We are proud to be among the first to unite the groups directly affected by these issues, in particular current and former professional athletes, with the scientists, physicians and entrepreneurs who will ultimately lead the way in developing solutions to these devastating problems. We believe that by educating athletes on the basics of concussions, and what additional resources are needed to achieve certain critical steps on the road to better treating the brain, we will give all parties a chance to partake in this emerging field of medical research.”

The #C4CT Conference will include presentations and panel discussions on the following key topics:

  1. Scientific understanding of Traumatic Brain Injury and the long-term scientific implications
  2. Current medical practice and what doctors believe are the key areas of unmet medical need
  3. Translational models available and additional tools needed to accelerate research

    4. …read more
    Source: FULL ARTICLE at DailyFinance